Indication assessment · §3
Prediabetes and progression to type 2 diabetes — trial records
Trial records in the Institute's register bearing on prediabetes and progression to type 2 diabetes.
§3Trials in this indication
10 trial records in the Institute's register bear on this indication, of which 2 are published trials.
Table 2. Trial records bearing on prediabetes and progression to type 2 diabetes.
| Record | Compound | Phase | Design | Randomised | Year |
|---|---|---|---|---|---|
| STEP-5 | Semaglutide | Phase 3 | Randomised, double-blind, placebo-controlled | 304 | 2022 |
| SCALE-PREDIABETES | Liraglutide | Phase 3 | Randomised, double-blind, placebo-controlled | 2,254 | 2017 |
| STEP-5-PKprogramme record | Semaglutide | Phase 1 | Phase 1 ascending dose | — | 2022 |
| SCALE-PREDIABETES-OLEprogramme record | Liraglutide | Phase 3 | Single-arm open-label | — | 2017 |
| STEP-5-RENAL-IMPprogramme record | Semaglutide | Phase 1 | Phase 1 ascending dose | — | 2022 |
| SCALE-PREDIABETES-ELDERLYprogramme record | Liraglutide | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2017 |
| STEP-5-HEPATIC-IMPprogramme record | Semaglutide | Phase 1 | Phase 1 ascending dose | — | 2022 |
| SCALE-PREDIABETES-BIOMARKERprogramme record | Liraglutide | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2017 |
| STEP-5-DDIprogramme record | Semaglutide | Phase 1 | Randomised crossover | — | 2022 |
| SCALE-PREDIABETES-DDIprogramme record | Liraglutide | Phase 1 | Randomised crossover | — | 2017 |
| This facet in the trial register. | |||||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DCW, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JPH. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine 2015;373(1):11–22. doi:10.1056/NEJMoa1411892 · PMID 26132939
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.
Compound Evidence Institute · CEI-IN-08/3 · https://compoundevidence.com/indications/prediabetes/trials/ · retrieved 30 July 2026